Ventura R, González G, Smeyers M T, de la Torre R, Segura J
Pharmacology Research Unit, Universitat Autònoma de Barcelona, Spain.
J Anal Toxicol. 1998 Mar-Apr;22(2):127-34. doi: 10.1093/jat/22.2.127.
A systematic study of the cross-reactivities of beta-adrenergic agonists and antagonists and their metabolites with an ELISA test designed to detect terbutaline and other beta 2-agonists has been performed in order to evaluate the applicability of this immunological test as screening method in routine human sports drug testing. Concentration response curves were calculated. IC50 values from 1.7 to 21.5 ng/mL were obtained for beta 2-agonists, and values from 3.1 to 520.8 ng/mL were obtained for most of the beta-blockers. The highest cross-reactivity was mainly depending on the amino substituent of the molecules although the structure of the aromatic ring was also important. Minor changes in the aromatic ring, such as 4-hydroxylation for propranolol, did not largely influence the IC50 value. Distribution of control activities (percentage of optical density as compared with a blank sample) of urines obtained in controlled excretion studies (70 samples) and urines collected after competition in sports in which beta-blockers are recommended to be tested (147 samples) showed a very small overlapping between the subpopulations of positive and negative samples. Cutoff values of 45 or 60% control activity were proposed for routine analysis. Sensitivity and specificity values of 92.8 and 98.8%, respectively (cutoff 45%), or 98.2 and 95.0%, respectively (cutoff 60%), were obtained. Because the known prevalence of positive results of beta-blockers and beta 2-agonists in the target population was very low, the predicted percentage of presumptive positive cases that would need further confirmation by gas chromatography-mass spectrometry was also low, accounting for a 1.48 and 5.28% (for the cutoffs of 45 and 60%, respectively) of the total number of samples to be screened by the presented ELISA test. Thus, in terms of time and cost savings, the ELISA test is a powerful tool for the purpose of screening for beta-adrenergic drugs in human urine.
为了评估这种免疫检测方法作为常规人体运动药物检测筛查方法的适用性,我们开展了一项系统性研究,该研究采用一种旨在检测特布他林和其他β2-肾上腺素能激动剂的酶联免疫吸附测定(ELISA)试验,检测β-肾上腺素能激动剂、拮抗剂及其代谢物的交叉反应性。计算了浓度-反应曲线。β2-肾上腺素能激动剂的半数抑制浓度(IC50)值为1.7至21.5 ng/mL,大多数β受体阻滞剂的IC50值为3.1至520.8 ng/mL。尽管芳香环的结构也很重要,但最高交叉反应性主要取决于分子的氨基取代基。芳香环的微小变化,如普萘洛尔的4-羟基化,对IC50值影响不大。在受控排泄研究(70个样本)中获得的尿液以及在推荐检测β受体阻滞剂的体育比赛后收集的尿液(147个样本)的对照活性分布(与空白样本相比的光密度百分比)显示,阳性和阴性样本亚群之间的重叠非常小。建议将45%或60%的对照活性作为常规分析的临界值。分别获得了灵敏度和特异性值,临界值为45%时,灵敏度和特异性分别为92.8%和98.8%;临界值为60%时,灵敏度和特异性分别为98.2%和95.0%。由于目标人群中β受体阻滞剂和β2-肾上腺素能激动剂阳性结果的已知患病率非常低,因此需要通过气相色谱-质谱法进一步确认的推定阳性病例的预测百分比也很低,分别占所提出的ELISA试验筛查样本总数的1.48%和5.28%(分别对应45%和60%的临界值)。因此,就节省时间和成本而言,ELISA试验是筛查人尿中β-肾上腺素能药物的有力工具。